Psyence Group ( (TSE:PSYG) ) just unveiled an announcement.
Psyence Biomedical, an associate of Psyence Group, has strengthened its Scientific Advisory Board by appointing Dr. Dan J. Stein, a leader in psychopharmacology. This move supports their ongoing Phase IIb clinical trial of psilocybin for Adjustment Disorder in Palliative Care and plans to explore Alcohol Use Disorder treatment. This expansion aims to introduce new psilocybin-based therapeutics to meet unmet needs in mental health and addiction, potentially enhancing the company’s positioning in the psychedelic therapeutics industry.
More about Psyence Group
Psyence Group is a life science biotechnology company listed on the Canadian Securities Exchange, focusing on natural psychedelics. Its associate, Psyence Biomed, is the first life science biotechnology company on the Nasdaq dedicated to developing botanical psilocybin-based psychedelic medicines, particularly for psychological trauma in palliative care.
YTD Price Performance: -25.00%
Average Trading Volume: 24,096
Technical Sentiment Signal: Buy
Current Market Cap: C$2.11M
See more insights into PSYG stock on TipRanks’ Stock Analysis page.